Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771973 | 1.00 | MPI (0.40) | MPIAKR1B1TSHRTDP1ALDH1A1 | |
| Phosphoric Acid SCHEMBL5792557 | 0.91 | MPI (0.48) | MPI | |
| SCHEMBL16600269 | 0.85 | MPI (0.33) | MPI | |
| SCHEMBL17984946 | 0.82 | MPI (0.39) | MPIAKR1B1 | |
| SCHEMBL17984945 | 0.77 | MPI (0.39) | MPIAKR1B1TSHRTDP1ALDH1A1 | |
| SCHEMBL6436950 | 0.76 | TSHR (0.33) | TSHRTDP1ALDH1A1 | |
| SCHEMBL16600605 | 0.75 | MPI (0.38) | MPIALDH1A1 | |
| SCHEMBL9842949 | 0.74 | TSHR (0.32) | TSHRTDP1ALDH1A1 | |
| SCHEMBL29876881 | 0.73 | TSHR (0.47) | TSHRTDP1ALDH1A1 | |
| SCHEMBL16600199 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281772-A1 | A NEURAL SUBSTRATE FOR SUGAR PREFERENCE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-05 | — | — | US | claimed |
| US-12351847-B2 | Methods for the improved formation of acarbose | UNIVERSITÄT BIELEFELD (DE) | 2025-07-08 | — | — | US | disclosed |
| CN-114555811-B | Methods for improving acarbose formation | 拜耳公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240110216-A1 | Production of Activated TDP-Deoxysugars in Recombinant Microorganisms | ZUCHEM INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11773423-B2 | Production of activated TDP-deoxysugars in recombinant microorganisms | ZUCHEM INC (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230227879-A1 | METHODS FOR THE IMPROVED FORMATION OF ACARBOSE | UNIVERSITÄT BIELEFELD (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3647430-B1 | MICROBIAL PRODUCTION OF FATTY AMINES | GENOMATICA INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| EP-1919486-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2008-05-14 | — | — | EP | disclosed |
| EP-1909802-A2 | STEROIDAL GLYCOSIDE COMPOUNDS AS CORE 2 GLCNAC-T INHIBITORS | BTG International Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007104576-A1 | MEDICAMENT COMPRISING N-ACETYLMANNOSAMINE OR DERIVATIVES THEREOF AND ITS USE | MOSETTER, KURT (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007035897-A2 | IMPROVED LIVE ATTENUATED VACCINE STRAIN FOR PREVENTION OF TULAREMIA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| WO-2007003948-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003957-A2 | STEROIDAL GLYCOSIDE COMPOUNDS AS CORE 2 GLCNAC- T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-H1817-H | Enzymatic methods for the preparation of pradimicins | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | MAN2A1, CSGALNACT1, MAN2B1 | MPI 105/4885AKR1B1 704/4885TSHR 1377/4885 |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | MPI 384/4885AKR1B1 421/4885TSHR 265/4885 |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | CSGALNACT1, ENGASE, GALNT6 | MPI 543/4885AKR1B1 413/4885TSHR 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.